Do you have any concerns about incorporating gedatolisib into the treatment landscape of HR+/HER2-, PIK3CA wild-type breast cancer (VIKTORIA-1)?

Hurvitz, et al. PMID: 41802242

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

How are you deciding between T-DXd/pertuzumab and THP> HP/tucatinib in patients with metastatic HER2+ breast cancer?

How do you select between imlunestrant ± abemaciclib and elacestrant for those with an ESR1 mutation and progressed on AI and CDK4/6 inhibitor for patients with metastatic ER+/HER2- breast cancer?

For first-line metastatic strongly ER/PR+, HER2-low IDC with neuroendocrine differentiation and the patient experiencing symptomatic visceral crisis, would you choose chemotherapy over CDK4/6i plus AI?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
Mobile App

Company

About
Careers
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.